Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Overview of partial compliance.

Stephen R Marder1

  • 1VA Greater Los Angeles Health Care System, West Los Angeles Health Center, and the Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, 90073, USA. marder@ucla.edu

The Journal of Clinical Psychiatry
|December 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward a Pluralistic Model for the Schizophrenia Spectrum-Dopamine and Beyond.

JAMA psychiatry·2026
Same author

A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 2: Perceived Changes in Subjective Quality of Life and Medication Satisfaction.

Schizophrenia bulletin open·2026
Same author

A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 1: Perceived Impact on Symptoms.

Schizophrenia bulletin open·2026
Same author

Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophrenia.

Schizophrenia research·2026
Same author

Finding a Medication for Negative Symptoms in Schizophrenia: Why So Many Failures?

The American journal of psychiatry·2026
Same author

Rethinking Antipsychotic Comparisons: The Role of Prior Exposure and Tolerability.

The American journal of psychiatry·2026
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Many patients with chronic illnesses, especially schizophrenia, do not take medications as prescribed. Noncompliance, often partial, is a key factor in relapse, influenced by side effects and understanding of treatment.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Patient Adherence

Background:

  • A significant number of patients with chronic psychiatric and nonpsychiatric illnesses exhibit poor medication adherence.
  • Studies indicate that over 50% of individuals with schizophrenia experience medication noncompliance at some point.
  • Partial compliance, where patients take only a portion of their prescribed dose, is common.

Purpose of the Study:

  • To identify factors contributing to medication noncompliance in patients with chronic illnesses, particularly schizophrenia.
  • To highlight the impact of noncompliance on relapse rates.
  • To discuss strategies for managing partial compliance.

Main Methods:

  • Review of existing studies on medication adherence in chronic illness populations.

Related Experiment Videos

  • Analysis of factors associated with noncompliance, including side effects, symptom severity, cognition, and patient understanding.
  • Examination of the discrepancy between patient/clinician estimates and actual compliance.

    • Main Results:

    • Medication noncompliance is a major contributor to relapse in schizophrenia.
    • Key factors influencing noncompliance include medication side effects, psychotic symptom severity, cognitive impairment, and insufficient understanding of medication's role in relapse prevention.
    • Both patients and clinicians tend to overestimate medication compliance.

    Conclusions:

    • Addressing medication noncompliance is critical for managing chronic illnesses, especially schizophrenia.
    • Strategies such as managing side effects, patient education, and utilizing long-acting formulations can improve adherence.
    • Improved understanding and management of partial compliance are essential for reducing relapse rates.